Current Location:home > Detailed Browse

Article Detail

Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia

Submit Time: 2020-02-28
Author: Zikuan Leng 1,5 ; Rongjia Zhu 2 ; Wei Hou 3 ; Yingmei Feng 3 ; Yanlei Yang 4 ; Qin Han 2 ; Guangliang Shan 2 ; Fanyan Meng 1 ; Dongshu Du 1 ; Shihua Wang 2 ; Junfen Fan 2 ; Wenjing Wang 3 ; Luchan Deng 2 ; Hongbo Shi 3 ; Hongjun Li 3 ; Zhongjie Hu 3 ; Fengchun Zhang 4 ; Jinming Gao 4 ; Hongjian Liu 5 ; Xiaoxia Li 6 ; Yangyang Zhao 2 ; Kan Yin 6 ; Xijing He 7 ; Zhengchao Gao 7 ; Yibin Wang 7 ; Bo Yang 8 ; Ronghua Jin 3 ; Ilia Stambler 9,10,11 ; Lee Wei Lim 9,10,12 ; Huanxing Su 9,10,13 ; Alexey Moskalev 9,10,14 ; Antonio Cano 9,10,15 ; Sasanka Chakrabarti 9,10,16 ; Kyung-Jin Min 9,10,17 ; Georgina Ellison-Hughes 9,10,18 ; Calogero Caruso 9,10,19 ; Kunlin Jin 9,10,20 ; Robert Chunhua Zhao 1,2,9,10 ;
Institute: 1.School of Life Sciences, Shanghai University, Shanghai, China.; 3.Beijing YouAn Hospital, Capital Medical University, Beijing, China; 5.Department of Orthopaedics, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.; 6.Institute of Stem Cell and Regeneration Medicine, School of Basic Medicine, Qingdao University, Shandong, China.; 7.Department of Orthopaedics, the Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China.; 8.Department of Neurosurgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.; 9.The Executive Committee on Anti-aging and Disease Prevention in the framework of Science and Technology, Pharmacology and Medicine Themes under an Interactive Atlas along the Silk Roads, UNESCO, Paris, France.; 10.International Society on Aging and Disease, Fort Worth, Texas, USA.; 11.The Geriatric Medical Center Shmuel Harofe , Beer Yaakov, affiliated to Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.; 12.School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.; 13.Institute of Chinese Medical Science, University of Macau, Taipa, Macau, China.; 14.Institute of Biology, Komi Science Center of Russian Academy of Sciences, Syktyvkar, Russia.; 15.Department of Pediatrics, Obstetrics and Gynecology, University of Valencia, Valencia, Spain.; 16.Department of Biochemistry, Maharishi Markandeshwar University, Kolkata, India.; 17.Department of Biological Sciences, Inha University, Incheon, South Korea.; 18.Faculty of Life Sciences & Medicine, King s College London, London, UK.; 19.Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Palermo, Italy.; 20.University of North Texas Health Science Center, Fort Worth, TX76107, USA.;

Abstracts

A coronavirus (HCoV-19) has caused the novel coronavirus disease (COVID-19) outbreak in Wuhan, China, Preventing and reversing the cytokine storm may be the key to save the patients with severe COVID-19 pneumonia. Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. This study aims to investigate whether MSC transplantation improve the outcome of 7 enrolled patients with COVID-19 pneumonia in Beijing YouAn Hospital, China from Jan 23, 2020. to Feb 16, 2020. The clinical outcomes, as well as changes of inflammatory and immune function levels and adverse effects of 7 enrolled patients were assessed for 14 days after MSC injection. MSCs could cure or significantly improve the functional outcomes of seven patients with COVID-19 pneumonia in 14 days without observed adverse effect. The pulmonary function and symptoms of all patients with COVID-19 pneumonia were significantly improved in 2 days after MSC transplantation. Among them, two common and one severe patient were recovered and discharged in 10 days after treatment. After treatment, the peripheral lymphocytes were increased and the overactivated cytokine-secreting immune cells CXCR3 CD4 T cells, CXCR3 CD8 T cells, and CXCR3 NK cells were disappeared in 3-6 days. And a group of CD14 CD11c CD11bmid regulatory DC cell population dramatically increased. Meanwhile, the level TNF-α is significantly decreased while IL-10 increased in MSC treatment group compared to the placebo control group. Furthermore, the gene expression profile showed MSCs were ACE2- and TMPRSS2- which indicated MSCs are free from COVID-19 infection. Thus, the intravenous transplantation of MSCs was safe and effective for treatment in patients with COVID-19 pneumonia, especially for the patients in critically severe condition.
Download Comment Hits:12026 Downloads:2624
From: 冷子宽
DOI:10.12074/202002.00080
Recommended references: Zikuan Leng,Rongjia Zhu,Wei Hou,Yingmei Feng,Yanlei Yang,Qin Han,Guangliang Shan,Fanyan Meng,Dongshu Du,Shihua Wang,Junfen Fan,Wenjing Wang,Luchan Deng,Hongbo Shi,Hongjun Li,Zhongjie Hu,Fengchun Zhang,Jinming Gao,Hongjian Liu,Xiaoxia Li,Yangyang Zhao,Kan Yin,Xijing He,Zhengchao Gao,Yibin Wang,Bo Yang,Ronghua Jin,Ilia Stambler,Lee Wei Lim,Huanxing Su,Alexey Moskalev,Antonio Cano,Sasanka Chakrabarti,Kyung-Jin Min,Georgina Ellison-Hughes,Calogero Caruso,Kunlin Jin,Robert Chunhua Zhao.(2020).Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia.[ChinaXiv:202002.00080] (Click&Copy)
Version History
[V1] 2020-02-28 05:54:17 chinaXiv:202002.00080V1 Download
Related Paper

Download

Current Browse

Change Subject Browse

Cross Subject Browse

  • - NO